Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Generative Artificial Intelligence (AI) In Drug Discovery Market Size Forecast: How Large Could The Market Become By 2030?

The market size for AI-driven clinical trial site feasibility has experienced a rapid expansion in recent years. It is projected to increase from $1.53 billion in 2025 to $1.89 billion in 2026, reflecting a compound annual growth rate (CAGR) of 23.6%. This historic growth has been driven by several factors, including the growing complexity of clinical trial designs, heightened cost pressures on drug development schedules, an increased dependence on data-informed trial planning, the expansion of global multi-site clinical trials, and the early integration of predictive analytics into trial feasibility processes.

The market for clinical trial site feasibility powered by artificial intelligence is projected to witness substantial expansion over the coming years. By 2030, its value is anticipated to reach $4.38 billion, reflecting a compound annual growth rate (CAGR) of 23.3%. This forecasted growth is driven by factors such as the widespread adoption of decentralized clinical trials, an increased demand for quicker site activation, a growing reliance on real-world evidence for feasibility decisions, the expansion of AI-enhanced trial planning platforms, and a heightened emphasis on mitigating trial risks. Key trends shaping this period include the incorporation of AI-driven models for site selection, the application of predictive analytics for patient recruitment, the integration of real-world data into feasibility assessments, the development of cloud-based feasibility solutions, and an intensified focus on forecasting trial performance.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp

#Generative Artificial Intelligence (AI) In Drug Discovery Market Growth Factors: Which Forces Are Supporting Market Expansion?

The increase in clinical trial activity is anticipated to drive expansion in the AI-driven clinical trial site feasibility market moving forward. Clinical trials encompass global research studies designed to evaluate the safety and effectiveness of novel medical therapies, drugs, and devices. This surge in trials is primarily fueled by growing investments in biomedical research and development, as both public and private sectors acknowledge the pressing demand for innovative solutions to tackle evolving healthcare issues. As trials proliferate, there is a heightened need for AI-powered site feasibility tools, enabling research organizations to efficiently pinpoint optimal locations, evaluate site capabilities, and forecast enrollment success for their studies. By April 2025, data from the Multidisciplinary Digital Publishing Institute, a Switzerland-based open-access scientific journal publisher, indicated that the clinicaltrials.gov website hosted a total of 404,637 interventional clinical trials. Consequently, the growing number of clinical trials is propelling the AI-powered clinical trial site feasibility market.

Generative Artificial Intelligence (AI) In Drug Discovery Market Segmentation Trends And Revenue Drivers

The artificial intelligence (AI)-powered clinical trial site feasibility market covered in this report is segmented –

1) By Component: Software, Services

2) By Deployment Mode: Cloud-Based, On-Premises

3) By Application: Site Selection, Patient Recruitment, Protocol Design, Performance Analytics, Other Applications

4) By End-User: Pharmaceutical Companies, Contract Research Organizations, Academic Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Software: Predictive Analytics Software, Machine Learning (ML) Platforms, Natural Language Processing (NLP) Tools, Data Visualization Software, Clinical Trial Management System (CTMS) Integration Software, Real-World Data (RWD) Analytics Software, Risk-Based Monitoring (RBM) Software

2) By Services: Feasibility Assessment Services, Site Selection Services, Patient Recruitment Support Services, Data Management And Analytics Services, Protocol Optimization Services, Regulatory Compliance Support Services, Consulting And Advisory Services

Generative Artificial Intelligence (AI) In Drug Discovery Market Industry Trends: What Changes Are Reshaping Demand?

Key players in the artificial intelligence-enabled clinical trial site feasibility market are concentrating on the creation of cutting-edge tools, specifically an AI-driven feasibility and recruitment platform aimed at refining site selection and boosting operational effectiveness throughout clinical trials. Such a platform functions as a software solution that employs artificial intelligence and machine learning to analyze trial protocols along with site data, pinpointing the most suitable clinical locations while improving patient recruitment by effectively matching eligible individuals, thereby shortening trial timelines and elevating study success rates. A notable example occurred in June 2023, when ObjectiveHealth, an integrated research and technology firm based in the United States, introduced ObjectiveScreen. This AI-powered feasibility and recruitment platform was designed to enhance clinical trial performance by improving patient identification, prequalification, and retention through real-time integration with electronic health records (EHRs), leveraging AI and machine learning algorithms in the process. By enabling clinical trial sites to directly access patient data, stratify health risks, and identify the most appropriate candidates, the platform accelerates enrollment and enhances trial outcomes.

#Generative Artificial Intelligence (AI) In Drug Discovery Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the artificial intelligence (AI)-powered clinical trial site feasibility market are Oracle Corporation, Thermo Fisher Scientific Inc., NVIDIA Corporation, IQVIA Holdings Inc., Labcorp Holdings Inc., Dassault Systèmes SE, Parexel International Corporation, ZS Associates Inc., Veeva Systems Inc., Verily Life Sciences LLC, Signant Health Holding Corp., Saama Technologies LLC, Elligo Health Research Inc., ConcertAI Inc., Medable Inc., Science 37 Inc., Castor EDC Inc., Unlearn.AI Inc., Antidote Technologies Inc., Deep 6 AI

Access The Complete Generative Artificial Intelligence (AI) In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Generative Artificial Intelligence (AI) In Drug Discovery Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the artificial intelligence (AI)-powered clinical trial site feasibility market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-powered clinical trial site feasibility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Generative Artificial Intelligence (AI) In Drug Discovery Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=28923&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model